These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32037284)

  • 1. The effect of nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: A randomized controlled trial.
    van der Werf A; Langius JAE; Beeker A; Ten Tije AJ; Vulink AJ; Haringhuizen A; Berkhof J; van der Vliet HJ; Verheul HMW; de van der Schueren MAE
    Clin Nutr; 2020 Oct; 39(10):3005-3013. PubMed ID: 32037284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocol.
    van der Werf A; Blauwhoff-Buskermolen S; Langius JA; Berkhof J; Verheul HM; de van der Schueren MA
    BMC Cancer; 2015 Mar; 15():98. PubMed ID: 25884881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer.
    Antoun S; Bayar MA; Dyevre V; Lanoy E; Smolenschi C; Ducreux M
    BMC Cancer; 2019 Aug; 19(1):847. PubMed ID: 31462288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
    Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis.
    Rinninella E; Cintoni M; Raoul P; Pozzo C; Strippoli A; Bria E; Tortora G; Gasbarrini A; Mele MC
    Clin Nutr; 2020 Jul; 39(7):2045-2054. PubMed ID: 31718876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
    Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
    Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
    Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.
    Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM
    J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical performance has a strong association with poor surgical outcome in older patients with colorectal cancer.
    Souwer ET; Moos SI; van Rooden CJ; Bijlsma AY; Bastiaannet E; Steup WH; Dekker JWT; Fiocco M; van den Bos F; Portielje JE
    Eur J Surg Oncol; 2020 Mar; 46(3):462-469. PubMed ID: 31899045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of oral nutritional supplements in post-discharge patients at nutritional risk following colorectal cancer surgery: A randomised clinical trial.
    Tan S; Meng Q; Jiang Y; Zhuang Q; Xi Q; Xu J; Zhao J; Sui X; Wu G
    Clin Nutr; 2021 Jan; 40(1):47-53. PubMed ID: 32563599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.
    Gallois C; Bourillon C; Auclin E; Artru P; Lièvre A; Lecomte T; Locher C; Marthey L; Faroux R; Pernot S; Barret M; Taieb J
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101603. PubMed ID: 33662782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
    Vashi PG; Gorsuch K; Wan L; Hill D; Block C; Gupta D
    PLoS One; 2019; 14(6):e0218761. PubMed ID: 31220163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.
    Mazzuca F; Roberto M; Arrivi G; Sarfati E; Schipilliti FM; Crimini E; Botticelli A; Di Girolamo M; Muscaritoli M; Marchetti P
    Integr Cancer Ther; 2019; 18():1534735419866920. PubMed ID: 31370717
    [No Abstract]   [Full Text] [Related]  

  • 16. Nutritional support in patients with colorectal cancer during chemotherapy: does it work?
    Dobrila-Dintinjana R; Trivanovic D; Zelić M; Radić M; Dintinjana M; Petranović D; Toni V; Vukelic J; Matijasic N
    Hepatogastroenterology; 2013 May; 60(123):475-80. PubMed ID: 23108082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of low skeletal muscle mass and density on short and long-term outcome after resection of stage I-III colorectal cancer.
    van Vugt JLA; Coebergh van den Braak RRJ; Lalmahomed ZS; Vrijland WW; Dekker JWT; Zimmerman DDE; Vles WJ; Coene PLO; IJzermans JNM
    Eur J Surg Oncol; 2018 Sep; 44(9):1354-1360. PubMed ID: 29914788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
    Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
    Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).
    Sasaki S; Oki E; Saeki H; Shimose T; Sakamoto S; Hu Q; Kudo K; Tsuda Y; Nakashima Y; Ando K; Akagi Y; Kakeji Y; Baba H; Maehara Y
    Int J Clin Oncol; 2019 Oct; 24(10):1204-1213. PubMed ID: 31062115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases.
    Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Tzeng CD; Chun YS; Lee JE; Vauthey JN; Aloia TA; Conrad C
    Surgery; 2019 Feb; 165(2):329-336. PubMed ID: 30197278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.